CLGN logo

CLGN
CollPlant Biotechnologies Ltd - Ordinary Shares New

623
Mkt Cap
$5.92M
Volume
30,567.00
52W High
$4.98
52W Low
$0.2711
PE Ratio
-0.44
CLGN Fundamentals
Price
$0.4106
Prev Close
$0.3829
Open
$0.3676
50D MA
$0.512
Beta
0.43
Avg. Volume
169,783.69
EPS (Annual)
-$0.9415
P/B
0.86
Rev/Employee
$60,794.87
$13.98
Loading...
Loading...
News
all
press releases
CollPlant Issues Letter to Shareholders
CollPlant Issues Letter to Shareholders CollPlant Issues Letter to Shareholders PR Newswire REHOVOT, Israel, April 13, 2026 REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant(NASDAQ: CLGN), a...
PR Newswire·19d ago
News Placeholder
More News
News Placeholder
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire REHOVOT, Israel, March 26, 2026 REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlantBiotechnologies (Nasdaq...
PR Newswire·1mo ago
News Placeholder
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement PR Newswire REHOVOT...
PR Newswire·1mo ago
News Placeholder
CollPlant Biotechnologies Launches Redesigned Corporate Website
CollPlant Biotechnologies Launches Redesigned Corporate Website CollPlant Biotechnologies Launches Redesigned Corporate Website PR Newswire REHOVOT, Israel, March 18, 2026 REHOVOT, Israel, March 18...
PR Newswire·2mo ago
News Placeholder
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS PR Newswire REHOVOT, Israel, March 11, 2026...
PR Newswire·2mo ago
News Placeholder
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal...
PR Newswire·2mo ago
News Placeholder
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex PR Newswire...
PR Newswire·2mo ago
News Placeholder
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments PR Newswire REHOVOT, Israel, Feb. 17, 2026...
PR Newswire·2mo ago
News Placeholder
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PR Newswire REHOVOT, Israel, Feb. 5, 2026...
PR Newswire·3mo ago
News Placeholder
CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention
The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.
Stocktwits·5mo ago
<
1
2
...
>

Latest CLGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.